文献速递儿童青少年精神

靶向剪接策略缓解神经连接蛋白1单倍体不足模型

Targeted splicing approach for alleviation of a neurexin 1 haploinsufficiency model.
PubMed 文献 · Mol Psychiatry · 2025-04-15

该研究在Nrxn1+/-小鼠中观察到海马CA3-CA1突触兴奋性传递缺陷及重复行为增加,通过遗传学方法排除剩余Nrxn1等位基因的剪接位点5插入,可恢复突触传递指标和重复行为至野生型水平,并部分恢复Nrxn1蛋白水平。

要点

  • Nrxn1+/-小鼠表现海马CA3-CA1突触兴奋性传递缺陷和重复行为增加。
  • 遗传排除Nrxn1剪接位点5可恢复突触传递指标和重复行为至野生型水平。
  • S5排除可能成为NRXN1相关神经精神障碍的治疗方向。

核心结论

  • 在Nrxn1+/-小鼠中,遗传排除剩余Nrxn1等位基因的剪接位点5可缓解突触传递缺陷和重复行为,提示S5排除可能是NRXN1相关神经精神障碍的有益治疗方向。

研究设计与样本

  • 研究使用Nrxn1+/-小鼠(缺失所有异构体α、β和γ)作为模型,并测试遗传排除剪接位点5的策略。

主要发现

  • Nrxn1+/-小鼠在海马CA3-CA1突触显示兴奋性突触传递缺陷,影响突触前和突触后特性,并表现出重复行为增加。
  • 在Nrxn1ΔS5/-小鼠中,遗传排除S5可恢复微小兴奋性突触后电流频率、配对脉冲比率、AMPA/NMDA比率和重复行为至野生型水平,并部分恢复Nrxn1蛋白水平。

临床怎么用

  • 该发现提示靶向Nrxn1剪接位点5的排除可能作为NRXN1单倍体不足相关神经精神障碍的潜在治疗策略。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

NRXN1 encoding the synaptic organizing protein neurexin 1 (Nrxn1) is among the strongest risk genes for autism spectrum disorders as well as other neuropsychiatric disorders. The most common contributing mutation is a deletion in one allele. While mice lacking one form of the protein, Nrxn1α, have been characterized, information is lacking on animal models with heterozygous deletion of all isoforms, as well as on therapeutic approaches directly targeting Nrxn1. We report that Nrxn1+/- mice with a deletion affecting all isoforms, α, β and γ, show deficits in excitatory synaptic transmission affecting presynaptic and postsynaptic properties at hippocampal CA3-CA1 synapses, and show increased repetitive behaviors. Based on previous studies indicating that exclusion of the insert at Nrxn1 splice site 5 (S5) boosts synaptic transmission, we tested S5 exclusion as a therapeutic approach. Genetic exclusion of S5 in the remaining Nrxn1 allele alleviated the deficits, restoring miniature excitatory postsynaptic current frequency, paired pulse ratio, AMPA/NMDA ratio, and repetitive behaviors to wild type levels and partially restoring Nrxn1 protein level in Nrxn1ΔS5/- compared to Nrxn1+/- mice. These data suggest that S5 exclusion may be a beneficial therapeutic direction in cases of neuropsychiatric disorders involving NRXN1.

来源:Mol Psychiatry,查看原文。版权归原作者所有。

引用

  1. Lu H, Roddick KM, Ge Y, et al. Targeted splicing approach for alleviation of a neurexin 1 haploinsufficiency model. Mol Psychiatry. 2025. PMID: 40234684. doi:10.1038/s41380-025-03017-w

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。